While GSK may be keen to sell, the asking price could be a stumbling block
In hindsight, it may be for the best. A single product consumer firm has it tough but it gets tougher when it’s housed in a company with multiple and bigger priorities. GlaxoSmithKline Plc (GSK) intends to divest—calling it a strategic review—its Horlicks and other nutrition products business, most of which it earns in India through its listed subsidiary GSK Consumer Healthcare Ltd. GSK will focus on pharmaceuticals and in consumer healthcare, it will focus on over-the-counter products and oral care.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.